NanoViricides Statistics
Total Valuation
NanoViricides has a market cap or net worth of $32.67 million. The enterprise value is $29.88 million.
| Market Cap | 32.67M |
| Enterprise Value | 29.88M |
Important Dates
The last earnings date was Monday, September 28, 2026, after market close.
| Earnings Date | Sep 28, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
NanoViricides has 25.53 million shares outstanding. The number of shares has increased by 33.55% in one year.
| Current Share Class | 25.53M |
| Shares Outstanding | 25.53M |
| Shares Change (YoY) | +33.55% |
| Shares Change (QoQ) | +2.99% |
| Owned by Insiders (%) | 0.50% |
| Owned by Institutions (%) | 9.29% |
| Float | 24.92M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 3.39 |
| P/TBV Ratio | 3.90 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.66
| Current Ratio | 2.66 |
| Quick Ratio | 2.35 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -101.46% and return on invested capital (ROIC) is -64.09%.
| Return on Equity (ROE) | -101.46% |
| Return on Assets (ROA) | -55.53% |
| Return on Invested Capital (ROIC) | -64.09% |
| Return on Capital Employed (ROCE) | -95.66% |
| Weighted Average Cost of Capital (WACC) | 13.37% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.17M |
| Employee Count | 7 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -11.11% in the last 52 weeks. The beta is 1.66, so NanoViricides's price volatility has been higher than the market average.
| Beta (5Y) | 1.66 |
| 52-Week Price Change | -11.11% |
| 50-Day Moving Average | 1.34 |
| 200-Day Moving Average | 1.27 |
| Relative Strength Index (RSI) | 47.12 |
| Average Volume (20 Days) | 667,143 |
Short Selling Information
The latest short interest is 587,622, so 2.30% of the outstanding shares have been sold short.
| Short Interest | 587,622 |
| Short Previous Month | 874,090 |
| Short % of Shares Out | 2.30% |
| Short % of Float | 2.36% |
| Short Ratio (days to cover) | 1.68 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -8.31M |
| Pretax Income | -8.22M |
| Net Income | -8.22M |
| EBITDA | -7.78M |
| EBIT | -8.31M |
| Earnings Per Share (EPS) | -$0.41 |
Balance Sheet
The company has $2.79 million in cash and no debt, with a net cash position of $2.79 million or $0.11 per share.
| Cash & Cash Equivalents | 2.79M |
| Total Debt | n/a |
| Net Cash | 2.79M |
| Net Cash Per Share | $0.11 |
| Equity (Book Value) | 8.68M |
| Book Value Per Share | 0.38 |
| Working Capital | 1.97M |
Cash Flow
In the last 12 months, operating cash flow was -$7.70 million and capital expenditures -$84,317, giving a free cash flow of -$7.78 million.
| Operating Cash Flow | -7.70M |
| Capital Expenditures | -84,317 |
| Depreciation & Amortization | 525,286 |
| Net Borrowing | n/a |
| Free Cash Flow | -7.78M |
| FCF Per Share | -$0.30 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
NanoViricides does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -33.55% |
| Shareholder Yield | -33.55% |
| Earnings Yield | -25.15% |
| FCF Yield | -23.81% |
Analyst Forecast
The average price target for NanoViricides is $6.00, which is 368.75% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $6.00 |
| Price Target Difference | 368.75% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 2 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on September 24, 2019. It was a reverse split with a ratio of 1:20.
| Last Split Date | Sep 24, 2019 |
| Split Type | Reverse |
| Split Ratio | 1:20 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |